Drug Profile
INCB 81776
Alternative Names: INCB081776; INCB81776Latest Information Update: 09 Aug 2023
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 02 May 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in Denmark, Netherlands, Sweden, Norway, USA (PO)
- 02 May 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in Netherlands, Denmark, Sweden, Norway, USA (PO)
- 15 Mar 2022 INCB 81776 is still in phase I trials for Solid-tumours (Combination therapy, Late-stage disease) in USA (PO) (Incyte corporation Form 10-K, March 2022)